Giuseppe Sofo

Dr. Giuseppe Sofo


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
PFPaul F. Funk
Paul F. Funk
Cosima C. HochCosima C. Hoch
Cosima C. Hoch
SKSamuel Alfons Christoph Knoedler
Samuel Alfons Christoph Knoedler
LKLeonard Knoedler
Leonard Knoedler
SCSebastian Cotofana
Sebastian Cotofana
MAMichael Alfertshofer
Michael Alfertshofer
(1) Background: As the field of artificial intelligence (AI) evolves, tools like ChatGPT are increasingly integrated into various domains of medicine, including medical education and research. Given the critical nature of medicine, it is of paramount importance that AI tools offer a high degree of reliability in the information they provide. (2) Methods: A total of n = 450 medical examination questions were manually entered into ChatGPT thrice, each for ChatGPT 3.5 and ChatGPT 4. The responses were collected, and their accuracy and consistency were statistically analyzed throughout the series of entries. (3) Results: ChatGPT 4 displayed a statistically significantly improved accuracy with 85.7% compared to that of 57.7% of ChatGPT 3.5 (p < 0.001). Furthermore, ChatGPT 4 was more consistent, correctly answering 77.8% across all rounds, a significant increase from the 44.9% observed from ChatGPT 3.5 (p < 0.001). (4) Conclusions: The findings underscore the increased accuracy and dependability of ChatGPT 4 in the context of medical education and potential clinical decision making. Nonetheless, the research emphasizes the indispensable nature of human-delivered healthcare and the vital role of continuous assessment in leveraging AI in medicine.

23 November 2023 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
SKSamuel Alfons Christoph Knoedler
Samuel Alfons Christoph Knoedler
LKLeonard Knoedler
Leonard Knoedler
HPHeli Patel
Heli Patel
FDFortunay H. Diatta
Fortunay H. Diatta
JCJustin M. Camacho
Justin M. Camacho
MKMartin Kauke-Navarro
Martin Kauke-Navarro

21 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
APAndrea Pagani
Andrea Pagani
Dominik ThorDominik Thor
Dominik Thor
Adriana C PanayiAdriana C Panayi
Adriana C Panayi
Silvan Maximilian KleinSilvan Maximilian Klein
Silvan Maximilian Klein
SGSebastian Geis
Sebastian Geis
Dominik DuscherDominik Duscher
Dominik Duscher
Autoimmune-induced alopecia, such as alopecia areata, involves immune-mediated damage to hair follicles, leading to significant hair loss. Emerging therapies that stabilize hypoxia-inducible factor 1-alpha (HIF-1α) show promise in counteracting follicular degradation and supporting hair regrowth. This communication highlights the potential of iron chelators, specifically deferoxamine (DFO) and deferiprone (DFP), to stabilize HIF-1α by reducing iron availability, thereby promoting vascularization, cellular proliferation, and a regenerative environment in the hair follicle niche. Clinical trials with iron chelators demonstrated improvements in hair density, thickness, and elasticity, as well as a reduction in hair loss by up to 66.8% over six months. These findings underscore the therapeutic potential of iron chelators in autoimmune alopecia management. Future research should explore the synergistic use of iron chelators with immune-modulating therapies, positioning them as viable options in the evolving field of alopecia treatment.